Anti-HER2 small molecule imaging agent - Affibody

Drug Profile

Anti-HER2 small molecule imaging agent - Affibody

Alternative Names: [111In]ABY-025; [68Ga]ABY-025; ABY-002; ABY-025; ABY0125; Anti-HER2 Affibody

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Affibody; GE Healthcare
  • Developer Affibody; Biomedical Radiation Sciences; Herlev Hospital; Swedish Cancer Society
  • Class Peptide fragments; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Breast cancer

Most Recent Events

  • 14 Jun 2018 Phase-II/III clinical trials in Breast cancer (Diagnosis) in Sweden (IV) (EudraCT2017-002115-34)
  • 18 May 2018 Affibody plans a phase II/III investigator led trial in Sweden, Denmark and Finland
  • 01 Apr 2018 Affibody Medical submits a clinical trial application for a phase II/III trial in Sweden, Denmark and Finland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top